Intensity Therapeutics, Inc. INTS
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -66.83%
- 1 year
- -89.70%
- Open
- 3.40
- Prev close
- 3.34
- Mkt cap
- 11.10M
- Vol
- 16.12K
- Avg vol
- 25.19K
- EPS
- -3.89
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.21
- High
- 3.46
- Forward P/E
- -1.66
- Beta
- 0.00
- Short ratio
- 3.05
- Inst. own
- 12.49%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 2.90
- 200-d avg
- 4.10
- 1y target
- 10.00
3M chart
Signals (14)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 28, 2026 | 3 days ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 7, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 30, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 25, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 20, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
Discussion (4)
Sign in to join the discussion
Who’s an idiot now?! It was so obvious that this study was based on weak fundamentals and unsupported data‼️ bulls, no worries, there’s always another game
Loading up this dip, ez $$$
VICKY HANUKA INTS 2 years ago #3Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target
Benzinga
·
08/24 08:52
1min
Intensity Therapeutics(INTS.US)
10.091
+152.28%
Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and maintains $12 price target.
Disclaimer: This content is for informational and educational purposes only and does not constitute
VICKY HANUKA INTS 2 years ago #4Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target
Benzinga
·
08/24 08:52
1min
Intensity Therapeutics(INTS.US)
10.091
+152.28%
Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and maintains $12 price target.
Disclaimer: This content is for informational and educational purposes only and does not constitute